Enzymatica AB (ENZY) AI Stock Analysis

• Market Cap: kr485.47M
• Dividend Yield: N/A
• Average Volume (3M): 87.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: 11.87%
• EPS Growth: 26.50%
• Country: SE
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 242,735,100
• 10 Day Avg. Volume: 55,841
• 30 Day Avg. Volume: 87,717
• PEG Ratio: 0.00
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 6.68
• P/FCF Ratio: -5.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: kr2.00 ▲(2.56% Upside)

Enzymatica AB's overall stock score is significantly impacted by its poor financial performance, characterized by persistent losses and negative cash flow. Technical analysis further indicates bearish momentum, with the stock trading below key moving averages and showing oversold conditions. Valuation metrics are unfavorable due to a negative P/E ratio and lack of dividend yield, reinforcing the stock's unattractiveness.

Enzymatica AB Business Overview & Revenue Model

Company Description

Enzymatica AB (ENZY) is a Swedish biotechnology company specializing in the development and commercialization of innovative health products based on enzymatic technology. The company operates primarily in the healthcare sector, focusing on respiratory health and oral care. Its core products include cold and flu remedies that leverage its proprietary enzyme technology to enhance the body's natural defenses and reduce symptoms, as well as mouth sprays and lozenges aimed at improving oral hygiene and health.

How the Company Makes Money

Enzymatica generates revenue primarily through the sale of its consumer health products in various markets, including pharmacy chains, health food stores, and online platforms. The company's main revenue streams come from its flagship product, ColdZyme, which is designed to prevent and alleviate cold symptoms, and other related products. Additionally, Enzymatica pursues partnerships with distributors and retailers to expand its market reach, which enhances sales volume. The company also invests in marketing and promotional activities to boost brand recognition and consumer adoption. Importantly, strategic collaborations with healthcare professionals and organizations contribute to its credibility and drive product recommendations, further supporting sales growth.

Enzymatica AB Financial Statement Overview

Summary

Enzymatica AB's financial health is concerning, with persistent losses and negative cash flow. While the company maintains a strong equity base and low leverage, its inability to generate profits and positive cash flows poses significant risks.

Income Statement

Enzymatica AB has faced consistent challenges in profitability, with negative net income and declining revenue. The net profit margin is negative due to substantial losses, and the gross profit margin has decreased over time. The company has not shown revenue growth, indicating struggles in market expansion or retention.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, signaling financial stability. However, the company has a negative return on equity due to ongoing losses. The debt-to-equity ratio is low, which is positive, but the lack of profitability remains a concern.

Cash Flow

Cash flow performance is weak, with negative operating cash flow and free cash flow. The company's reliance on financing activities to support operations raises concerns about sustainability. The cash flow coverage ratios are unfavorable, reflecting ongoing operational challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	50.29M	45.58M	50.90M	48.95M	57.24M	111.25M
Gross Profit	33.25M	30.72M	31.86M	28.45M	33.35M	75.96M
EBITDA	-51.53M	-49.23M	-41.12M	-59.97M	-38.19M	-5.23M
Net Income	-52.98M	-53.18M	-49.73M	-68.66M	-45.39M	-13.22M
Balance Sheet
Total Assets	154.69M	195.22M	125.91M	174.41M	157.04M	162.03M
Cash, Cash Equivalents and Short-Term Investments	45.29M	75.21M	8.37M	50.69M	31.62M	24.02M
Total Debt	1.59M	2.20M	18.08M	22.32M	2.60M	14.47M
Total Liabilities	10.96M	18.86M	49.30M	48.12M	32.07M	55.38M
Stockholders Equity	143.73M	176.37M	76.61M	126.29M	124.97M	106.65M
Cash Flow
Free Cash Flow	-64.34M	-60.90M	-41.02M	-68.28M	-42.00M	-15.49M
Operating Cash Flow	-64.07M	-60.51M	-40.29M	-64.57M	-35.87M	-10.65M
Investing Cash Flow	-246.00K	-393.00K	-730.00K	-3.72M	-6.13M	-4.84M
Financing Cash Flow	101.40M	127.65M	-1.39M	87.37M	49.53M	10.02M

Enzymatica AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ENZY, the sentiment is Negative. The current price of 1.95 is below the 20-day moving average (MA) of 2.02, below the 50-day MA of 2.23, and below the 200-day MA of 2.68, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 38.84 is Neutral, neither overbought nor oversold. The STOCH value of 29.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ENZY.

Enzymatica AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORX	―	kr953.40M	―	―	―	-8.79%	-91.09%
ALZCUR	―	kr252.81M	―	-161.07%	―	―	22.73%
KLAR	―	kr122.50M	―	-3899.10%	―	1523.75%	20.82%
NANEXA	―	€305.97M	―	-34.87%	―	-38.56%	69.37%
ENZY	―	kr485.47M	―	―	―	11.87%	26.50%